Scale -


  • Ebitda is 15.89 Rs Cr; 5 Year CAGR is 79 %; Annual Decline is -26 %
  • PBT is 0.49 Rs Cr; Annual Decline is -38 %; Continuous Decline over 3 years
  • PAT is 7.43 Rs Cr; Annual Decline is -23 %
  • Quarterly Revenue is 20.72 Rs Cr; Continuous Decline over 3 Quarters
  • Quarterly Ebitda is 2.35 Rs Cr; Continuous Decline over 3 Quarters

Profitability -


  • PBDIT Margin is 13.83 %; 5 Year CAGR is 82 %; Annual Decline is -24 %
  • PAT Margin is 6.47 %; Annual Decline is -20 %

Return -


  • ROCE is 28.5 %; in Top Quartile; Annual Decline is -54 %
  • ROA is 7.2 %; in Top Quartile
  • ROE is 41.94 %; in Top Quartile; Annual Decline is -57 %
  • Asset Turnover is 107 %; in Top Quartile

Efficiency -


  • Current Ratio is 1.04; Continuous Growth over 3 years; in Bottom Quartile
  • Quick Ratio is 0.61; Continuous Growth over 3 years; in Bottom Quartile
  • Inventory Turnover Ratio is 3.78; Continuous Growth over 3 years
  • Operating cash flow is 10.84 Rs Cr; Annual Decline is -49 %

Solvancy -


  • Debt/Equity is 1.95; Annual Decline is -40 %; Continuous Decline over 3 years; in Top Quartile
  • Contingent Liabilities is 0 Rs Cr; Annual Decline is -100 %
  • Long term Debt is 22.81 Rs Cr; Annual Growth is 120 %; in Top Quartile

Quality -


  • Operating cashflow/PAT is 146 %; in Top Quartile; Annual Decline is -34 %
  • Current Tax/PAT is 14 %; in Bottom Quartile
  • Operating cashflow/ebitda is 68 %; Annual Decline is -31 %; Continuous Decline over 3 years
  • Change in Inventories/Total Expenses is 4 %; Annual Growth is 220 %; in Top Quartile
  • Other Expenses/Total Expenses is 17 %; Continuous Growth over 3 years
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Roxadustat Market Outlook Signals Expansion To $9.56 Billion Through 2030
Montelukast Sodium Market Report Provides Insights Into Market Evolution And Growth Prospects
Kimia Biosciences Ltd. Estimates – BSE:KIMIABL
Kimia Biosciences AGM approves borrowing limits and director appointments